The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALLERGAN INC | COM | 018490102 | 143,837 | 850,000 | SH | Call | SOLE | 850,000 | 0 | 0 | |
| APPLIED MATLS INC | COM | 038222105 | 57,636 | 2,555,900 | SH | Call | SOLE | 2,555,900 | 0 | 0 | |
| APPLIED MATLS INC | COM | 038222105 | 5,008 | 222,100 | SH | SOLE | 222,100 | 0 | 0 | ||
| VALEANT PHARMACEUTICALS INTL | COM | 91911K102 | 69,997 | 555,000 | SH | Call | SOLE | 555,000 | 0 | 0 | |
| VALEANT PHARMACEUTICALS INTL | COM | 91911K102 | 378 | 3,000 | SH | SOLE | 3,000 | 0 | 0 | ||